MedTrace Logo

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza

NCT00640302 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2012-04-24

No results posted yet for this study

Summary

This aim of this project is to evaluate the efficacy of neuraminidase inhibitors in patients who have a clinical diagnosis of pandemic influenza infection. The study is observational only. The primary measure used in this study will be mortality. Symptom severity and duration, treatment limiting side effects, demographic information and resistance will also be examined. This project will commence upon pandemic influenza being declared in Australia, Hong Kong or Singapore. Data will be analysed as quickly as possible to help inform the continued use of neuraminidase inhibitor therapy as a cornerstone of the public health agency response to pandemic influenza.

Conditions

  • Pandemic Influenza

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • Dominic Dwyer, FRACP, FRCPA, MD · Westmead Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00640302 on ClinicalTrials.gov